Publisher's Synopsis
The importance of circulation variations in cardiovascular diseases has led to a growing acceptance among clinicians that effective therapy should provide complete protection over the full 24-hour period. If patient compliance is poor, the problems of providing round-the-clock treatment are compounded. Recognizing the importance of patient compliance in cardiovascular therapy, the XIIth Congress of the European Society of Cardiology concentrated on this particular issue. A whole session of the Congress was devoted to amlodipine, a new calcium antagonist which provides 24-hour calcium entry blockade following once-daily administration. This symposium report should be of interest to all those involved with the treatment of cardiovascular diseases.
